TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from SanBio Co ( (JP:4592) ) is now available.
SanBio Co. reported its consolidated financial results for the fiscal year ending January 31, 2025, showing a reduction in net losses compared to the previous year. Despite ongoing financial challenges, including negative operating and ordinary income, the company remains committed to its strategic goals, with no significant changes in accounting policies or consolidation scope.
More about SanBio Co
SanBio Co. is a company listed on the Tokyo Stock Exchange, operating in the biotechnology industry. The company focuses on developing regenerative cell medicines, aiming to address unmet medical needs in the field of neurological disorders.
YTD Price Performance: 40.86%
Average Trading Volume: 1,013
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $558.9M
Learn more about 4592 stock on TipRanks’ Stock Analysis page.